Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK and NKT Cell Immunotherapy in Non Small Cell Lung Cancer
NCT03198923Phase 1Unknown
- Start
- Sep 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC). Primary endpoints: Adverse Events at 30 days and Overall Survival at 3 years. Status: unknown.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03198923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198923.